Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 1215Neoplasms 1024Carcinoma, Non-Small-Cell Lung 747Prostatic Neoplasms 687Colorectal Neoplasms 590Lung Neoplasms 572Pancreatic Neoplasms 394Leukemia, Myeloid, Acute 394Neoplasm Metastasis 387Ovarian Neoplasms 370Multiple Myeloma 369Stomach Neoplasms 316Carcinoma, Hepatocellular 301Melanoma 281Brain Neoplasms 277Recurrence 273Squamous Cell Carcinoma of Head and Neck 267Head and Neck Neoplasms 237Endometrial Neoplasms 234Glioblastoma 233Triple Negative Breast Neoplasms 228Uterine Cervical Neoplasms 221Precursor Cell Lymphoblastic Leukemia-Lymphoma 221Lymphoma 221Sarcoma 201Hematologic Neoplasms 199Urinary Bladder Neoplasms 196Esophageal Neoplasms 190Carcinoma, Renal Cell 187Lymphoma, Non-Hodgkin 175

Interventions

Cisplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Non-Small Cell Lung Cancer With HER2- Mutations × 1 year × Clear all
NCT06430437 2026-01-21

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
300 enrolled
Thoracic

Non-Small Cell Lung Cancer With HER2- Mutations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡